Hucog HP

Hucog HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for precision in fertility treatments and specific endocrine disorders. Manufactured under stringent quality controls, it offers reliable luteinizing hormone (LH) activity to support ovulation induction, corpus luteum maintenance, and testosterone production. Its high purity reduces the risk of impurities, making it a trusted choice among reproductive endocrinologists and urologists for targeted therapeutic outcomes.

Features

• Contains highly purified human chorionic gonadotropin (hCG)
• Available in multiple strengths, commonly 5000 IU and 10,000 IU per vial
• Lyophilized powder form for reconstitution with provided solvent
• Subcutaneous or intramuscular administration
• Manufactured in compliance with cGMP standards
• Each batch undergoes rigorous purity and potency testing

Benefits

• Promotes final follicular maturation and triggers ovulation in women undergoing assisted reproductive technology (ART)
• Supports corpus luteum function to enhance progesterone production post-ovulation
• Stimulates Leydig cells in men to support testosterone synthesis and treat hypogonadism
• May aid in cryptorchidism management in pediatric patients under specialist supervision
• High purity minimizes adverse reactions and improves patient tolerance
• Provides predictable pharmacokinetics for precise dosing in complex treatment protocols

Common use

Hucog HP is primarily indicated for the treatment of female infertility, particularly in conjunction with other gonadotropins for controlled ovarian hyperstimulation. It is used to induce ovulation in anovulatory women and final oocyte maturation prior to retrieval in in vitro fertilization (IVF) cycles. In males, it is prescribed for hypogonadotropic hypogonadism to stimulate testosterone production and, in prepubertal cryptorchidism not due to anatomical obstruction, to induce testicular descent. Off-label uses may include weight loss protocols in combination with very low-calorie diets, though this application remains controversial and is not universally endorsed.

Dosage and direction

Dosage must be individualized based on the patient’s condition, response, and treatment protocol. For ovulation induction in women: 5,000 to 10,000 IU administered as a single injection one day following the last dose of follicle-stimulating agent. For corpus luteum support: 1,000 to 2,500 IU administered at the time of embryo transfer and repeated every 2–3 days in early pregnancy under medical supervision. For male hypogonadism: 1,000 to 4,000 IU administered 2 to 3 times weekly for several weeks or months, with adjustments based on testosterone levels. Reconstitute with provided sodium chloride solution; administer via subcutaneous or intramuscular injection using aseptic technique. Rotate injection sites to minimize tissue irritation.

Precautions

Use under strict medical supervision with regular monitoring of ovarian size via ultrasound to avoid ovarian hyperstimulation syndrome (OHSS) in women. In men, monitor testosterone levels, hematocrit, and prostate-specific antigen (PSA) periodically. Use with caution in patients with asthma, epilepsy, migraine, or renal or cardiac impairment due to potential fluid retention. May cause hypersensitivity reactions; have emergency equipment available during initial administration. Not recommended for use in patients with hormone-dependent malignancies unless benefits outweigh risks. Pediatric use requires careful benefit-risk assessment by a specialist.

Contraindications

Hypersensitivity to hCG or any component of the formulation. Prior allergic reaction to any gonadotropin product. Presence of uncontrolled thyroid or adrenal dysfunction. Ovarian, uterine, or breast carcinoma in females; prostate carcinoma or other androgen-dependent neoplasms in males. Organic intracranial lesions such as pituitary tumors. Abnormal uterine bleeding of undetermined origin. Primary ovarian failure. Cryptorchidism due to mechanical obstruction or previous orchidopexy. Pregnancy outside of supervised fertility treatment protocols.

Possible side effect

Common: injection site reactions (pain, redness, swelling), headache, irritability, restlessness, fatigue. In women: mild to moderate ovarian enlargement, abdominal pain, OHSS (in severe cases, characterized by rapid weight gain, abdominal pain, nausea, vomiting, dyspnea, oliguria), breast tenderness. In men: gynecomastia, acne, precocious puberty in pediatric patients, increased libido. Rare: arterial thromboembolism, allergic reactions including anaphylaxis, ectopic pregnancy, multiple gestations.

Drug interaction

Potential interactions with gonadotropin-releasing hormone (GnRH) analogs, which may alter pituitary response. Concurrent use with corticosteroids may exacerbate fluid retention. May interfere with interpretation of diagnostic tests for pituitary, thyroid, adrenal, or gonadal function. No well-documented interactions with broad-spectrum antibiotics or anticoagulants, but caution is advised with any concomitant medication affecting hormonal balance.

Missed dose

If a dose is missed, administer as soon as possible unless it is near the time of the next scheduled dose. Do not double the dose to catch up. Consult the prescribing physician for guidance, as timing is critical in ovulation induction protocols. In male hormone therapy, adjust subsequent doses based on clinical response and serum testosterone levels under medical advice.

Overdose

Overdose may lead to severe OHSS in women, characterized by ovarian enlargement, ascites, hydrothorax, and in extreme cases, thromboembolic events. In men, excessive doses can cause exaggerated androgen effects such as aggressive behavior, excessive gynecomastia, or polycythemia. Treatment is supportive and symptomatic: discontinue hCG, monitor vital signs and fluid/electrolyte balance, and provide medical management for specific complications. There is no specific antidote.

Storage

Store unopened vials at 2–8°C (36–46°F); do not freeze. Protect from light. After reconstitution, use immediately or store refrigerated for up to 30 days if aseptic technique is maintained; however, immediate use is recommended to ensure sterility and potency. Do not use if solution is discolored or contains particulate matter. Keep out of reach of children and pets.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Hucog HP is a prescription medication and must be used under the direction of a qualified healthcare professional. Always follow your physician’s instructions and report any adverse effects promptly. The manufacturer and distributor are not liable for misuse or incorrect administration.

Reviews

Clinical studies and expert reviews highlight Hucog HP’s efficacy in triggering ovulation and supporting luteal phase function, with high rates of oocyte maturation and pregnancy success in appropriately selected patients. Users report reliable results when protocols are followed precisely, though individual responses may vary. Some note injection site discomfort, but overall tolerability is considered favorable compared to older, less purified formulations. Long-term use in male hypogonadism shows sustained testosterone production with dose-dependent efficacy.